Literature DB >> 19727559

Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab.

Carlos Eduardo Paiva1, Yara Cristina de Paiva Maia, Bianca Sakamoto Ribeiro Paiva, Mauro Masson Lerco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19727559     DOI： 10.1007/s10637-009-9312-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

1.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

Authors:  Tomomi Kamba; Betty Y Y Tam; Hiroya Hashizume; Amy Haskell; Barbara Sennino; Michael R Mancuso; Scott M Norberg; Shaun M O'Brien; Rachel B Davis; Lori C Gowen; Keith D Anderson; Gavin Thurston; Shuji Joho; Matthew L Springer; Calvin J Kuo; Donald M McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-19       Impact factor: 4.733

Review 2.  Understanding and managing the possible adverse effects associated with bevacizumab.

Authors:  Stacy S Shord; Linda R Bressler; Lauryn A Tierney; Sandra Cuellar; Amina George
Journal:  Am J Health Syst Pharm       Date:  2009-06-01       Impact factor: 2.637

Review 3.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.

Authors:  Sanjaykumar Hapani; David Chu; Shenhong Wu
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

4.  Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: implications for angiogenesis and ulcer healing.

Authors:  Dolgor Baatar; Michael K Jones; Koji Tsugawa; Rama Pai; Woo S Moon; Gou Y Koh; Injune Kim; Seigo Kitano; Andrzej S Tarnawski
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 5.  Treatment in advanced colorectal cancer: what, when and how?

Authors:  I Chau; D Cunningham
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

6.  Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.

Authors:  J Tol; A Cats; L Mol; M Koopman; M M E M Bos; J J M van der Hoeven; N F Antonini; J H J M van Krieken; C J A Punt
Journal:  Invest New Drugs       Date:  2008-03-12       Impact factor: 3.850
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.